Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...
Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period.
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License...
Student researchers from Mississippi State University and The Ohio State University received Boehringer Ingelheim research awards
DULUTH, Ga., Aug. 11, 2025 /PRNewswire/ -- Veterinary research took...
Market opportunities for mRNA synthesis raw materials lie in the growing demand for high-purity materials driven by mRNA therapeutics. Key drivers include advancements in mRNA technology, regulatory compliance, and supply chain resilience. Emerging applications in personalized medicine and gene editing further boost this market.
Market opportunities for mRNA synthesis raw materials lie in the growing demand for high-purity materials driven by mRNA therapeutics. Key drivers include advancements in mRNA technology, regulatory compliance, and supply chain resilience. Emerging applications in personalized medicine and gene editing further boost this market.
L.A. Film School graduates contribute across 22 nominated projects, with two earning individual honors in top categories, reinforcing the college's entertainment industry impact.
LOS ANGELES,...
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant in a registered direct offering. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period.
The new YouTube Player for Education focuses students on learning by showing videosdistraction-free
SALT LAKE CITY, Aug. 8, 2025 /PRNewswire/ -- Instructure, the world's leading edtech...
Hong Kong, Aug. 7, 2025 /PRNewswire/ -- Hong Kong-based digital transformation consultancy Big Jump Digital announced today that its AI marketing platform has successfully delivered...
Conference Unites Diverse Disciplines to Explore the Expanding Role of Artificial Intelligence in Creativity, Computation, and Connection.
VANCOUVER, BC, Aug. 6, 2025 /PRNewswire/ -- From...
SHENZHEN, China, Aug. 5, 2025 /PRNewswire/ -- Following the great response to VIOFO A329, VIOFO launched the A329S 3CH in response to the requests for...